-
4 kinds of food have the risk of cancer, but many people eat every day! To stay away from cancer, you have to take the table off
Time of Update: 2021-02-12
As early as 1993, aflatoxin was classified as a class 1 carcinogen, which is 70 times more carcinogenic than methamphetamine and 68 times more toxic than frost, so eating moldy foods regularly is likely to cause liver cancer.
-
Br J Cancer: Multi-exercise reduces the risk of colorectal cancer
Time of Update: 2021-02-12
the role of these tool variables in the genome-wide association study of colorectal cancer, which included 31,197 cases and 61,770 controls, was analyzed through MR research.
further studies showed no association between sedentation and the risk of colorectal cancer.
-
2020 Tumor New Drug Data Card - Vibutoxi monoantigen
Time of Update: 2021-02-12
Adcetris has been approved in China for the treatment of adult patients with recurring/reassociative CD30-positive classic Hodgkin's lymphoma (cHL) or systemic interdational large cell lymphoma (sALCL).
-
Clin Cancer Res: Quantified tumor mutation load based on ctDNA is a good predictor of whether metastasis NSCLC patients will benefit from immunotherapy
Time of Update: 2021-02-12
with the new bTMB algorithm and the best bTMB threshold (≥20 mut/Mb), high bTMB is a predictive indicator that metastasis NSCLC patients benefit from durvalumab-tremelimumab or chemotherapy.
-
Br J Cancer: CYP3A7 rs45446698 SNP: Factors associated with pre-menopaan estrogen and progesterone levels associated with hormone-positive breast cancer risk
Time of Update: 2021-02-12
estrogen-3-glucosides and progesterol-3-glucosides are urine metabolites of estrogen and progesterone, respectively, in a study designed to identify genetic mutations associated with levels of sex hormones in the urine and the risk of breast cancer.
-
Fatal obesity, cancer is fat man's fate?!
Time of Update: 2021-02-12
To clarify the accuracy of the theory that "healthy fat people" are really healthy, experts at European universities conducted a large observational study that assessed the association between different body mass index (BMI) and physical activity levels and major CVD risk factors.
-
7.5 people in China are diagnosed with cancer every minute! What do you know about this healthy killer?
Time of Update: 2021-02-12
According to the 2019 National Cancer Statistics released by the National Cancer Center, there are about 3.929 million malignant tumors in China each year, with about 2.338 million deaths and 7.5 people diagnosed with cancer every minute.
-
Br J Cancer: The prognosis of esterase gene expression levels in multiple myeloma
Time of Update: 2021-02-12
In this study, esterase gene expression spectrum from multiple myeloma samples from the FIMM dataset, the researchers performed gene expression spectrometry analysis through the Finnish Institute of Molecular Medicine (FIMM) queue to assess the relevant genomic mutations and obtain corresponding bone marrow punctures from newly diagnosed MM (NDMM) patients or patients with recurring/refroutable MM (RRMM).
-
Eur Radiol: What signs on MRI indicate tumor progression for low-risk prostate cancer?
Time of Update: 2021-02-12
PRECISE scoring system has good diagnostic efficacy in assessing the progression of prostate cancer tumors, and its high NPV may help reduce the number of follow-up biopsies required in AS patients.
-
J Clin Oncol: Issue III | Pym monoanti-anti-ipi mono-anti-treatment PD-L1 TPS≥50% metastasis NSCLC (KEYNOTE-598)
Time of Update: 2021-02-12
study was a randomized, double-blind Phase III trial (KEYNOTE-598) that recruited previously untreated PD-L1 TPS≥50% and did not carry a metastasis NSCL with sensitive EGFR or APK variants In patients with C, random (1:1) was assigned to the Ipi monoantigen (1 mg/kg,6 weeks x 18 times) or placebo group; all patients received pym monoantigen (200 mg) every 3 weeks for a total of 35 doses.
-
J Clin Oncol: The efficacy and safety of the new selective ER degradation agent Elacestrant for the treatment of ER-HER2-advanced breast cancer
Time of Update: 2021-02-12
The Phase I RAD1901-005 study evaluated the efficacy and safety of elacestrant, an experimental oral selective estrogen-inhibitor (SERD) for estrogen-positive, human-skin growth factor-like 2-negative metastasis breast cancer patients, including those with mutations in the estrogen-infested gene α (ESR1).
-
J Clin Oncol: Bone marrow growth abnormality syndrome | Individualized prognostic prediction based on clinical and genetic characteristics
Time of Update: 2021-02-12
the probability of survival after transplantation of allogeneic hematocytes in different groups of patients, by integrating 63 clinical and genomic variables, the researchers developed a new prognostic model that can generate personalized survival predictions.
-
JCO: The objective remission rate of the first-line treatment of advanced opaque cell kidney cancer in The first-line treatment of Pabliju monotherapy can reach 26.7%
Time of Update: 2021-02-11
Paboli juju monotherapy provides long-lasting anti-tumor activity (ORR - 26.7%) in patients with untreated advanced non-transparent cellular kidney cancer (nccRCC), which may be a potential treatment option for nccRCC.
-
How to treat PD-1 incurable eye melanoma? Anti-CD40 antibody YH003 in union with Toripalimab
Time of Update: 2021-02-11
The trial is a multi-center, open-label study with a multi-dose upgrade phase designed to assess the safety, tolerance, pharmacogenetics and initial efficacy of YH003 in the joint treatment of advanced solid tumors with Toripalimab; for example, a 68-year-old woman with eye melanoma and liver metastasis is resistant to a joint protocol of first-line Nivolumab (anti-PD-1 antibody) and second-line Nivolumab/Ipilimumab (anti-CTLA-4 antibody).
-
J Natl Cancer Inst: How do you eat aspirin, when do you start eating it, and how long do you eat it to prevent colorectal cancer?
Time of Update: 2021-02-11
In long-term patients, aspirin is not dose-dependent on colorectal cancer prevention; compared to the standard (325 mg)-dose tablets/week; aspirin dose is 0.5-lt;1.5, 1.5-lt.
-
Nature: Yuan Gang and others found that the increased activity of NSD3 histoprotein methylation led to the occurrence of lung squamous cell carcinoma
Time of Update: 2021-02-11
NSD3 expression is closely related to gene amplification compared to other 8p11-12 candidate LUSC drivers.
in the LUSC mouse model, the knock-off of NSD3, rather than FGFR1, reduced tumor growth and prolonged survival.
-
Clin Cancer Res: Combined inhibition of G alpha and MEK can significantly improve the therapeutic effect of grape membrane melanoma
Time of Update: 2021-02-11
the cell system and human grape membrane melanoma cell lines were used in heterogeneous transplantation studies to evaluate the therapeutic activity of single G alphaq inhibition and combined MEK inhibition.
-
J Natl Cancer Inst: Can eating aspirin after being diagnosed with colorectal cancer also reduce the risk of death?
Time of Update: 2021-02-11
Although subjects who started taking aspirin regularly after diagnosis had a lower risk of CRC-specific death than those who did not use aspirin before or after diagnosis, neither aspirin nor non-aspirin NSAID significantly reduced CRC specific mortality (average follow-up 9.4 years; HR 0.82) after diagnosis.
-
The results of Sino-US pharmaceutical cooperation have been approved for first-line treatment of lung cancer patients
Time of Update: 2021-02-11
The State Drug Administration on the 3rd approved the innovative drug PD-1 inhibitor Dabershu, combined chemotherapy for EGFR gene mutation and APK negative, non-surgical removal of local late stage or metastasis non-squamous non-small cell lung cancer patients first-line treatment.
-
Ace breast cancer products actively reduce prices by more than 50%, Pfizer in China's tumor market how to do?
Time of Update: 2021-02-11
Under the goal of "bringing breakthrough innovation to change patients' lives" and patient-centered win-win development strategy, how to accelerate product introduction, how to lay out and match different market strategies and access methods for different products, the transformation of Pfizer needs to continue to prove its market dominance and competitiveness.
